Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug
This study has been completed.
Sponsor:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00520663
First received: August 23, 2007
Last updated: May 31, 2012
Last verified: February 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to define the absorption, breakdown and excretion of a single dose of radiolabelled SB-649868 and its breakdown products by measuring their concentration in blood, urine and faeces over a 7-10 day period. "Radiolabelled" means that the test drug has a radioactive component to help us track the drug. The safety and tolerability of the test drug will also be assessed.
| Condition | Intervention | Phase |
|---|---|---|
|
Sleep Initiation and Maintenance Disorders Insomnia |
Drug: 14C-SB649868 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-label Study to Determine the Excretion, Balance and Pharmacokinetics of SB649868 After a Single Oral Administration of 14C-SB649868 in Healthy Volunteers |
Resource links provided by NLM:
Further study details as provided by GlaxoSmithKline:
Primary Outcome Measures:
- Excretion of SB649868 by measuring radioactivity in urine and faeces [ Time Frame: over 7-10 days. ]
- Plasma levels of SB-649868 by measuring drug levels and radioactivity in plasma. Plasma, urine,faeces samples to study the metabolites of SB649868. [ Time Frame: over 4 days ]
Secondary Outcome Measures:
- Safety and tolerability of 14C-SB649868 by adverse event monitoring, lab samples and cardiovascular monitoring. [ Time Frame: over the course of the study ]
| Enrollment: | 8 |
| Study Start Date: | June 2007 |
| Study Completion Date: | August 2007 |
| Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: 14C-SB649868
Other Name: 14C-SB649868
Eligibility| Ages Eligible for Study: | 30 Years to 55 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion criteria:
- Healthy males, aged 30-55 years inclusive.
- Body weight more or equal to 50kg with a BMI (body mass index) between 18.5-29.9kg/m2 inclusive.
- Healthy as based on a medical evaluation consisting of medical history, physical examination, lab tests on blood and urine and cardiovascular monitoring.
LH, FSH and testosterone hormones must be within normal reference range.
Exclusion criteria:
- Positive urine drug screen or alcohol breath test at screening visit.
- Average weekly alcohol intake of more than 21 units or average daily intake of more than 3 units.
- Grapefruit or grapefruit juice intake 7 days before dosing and until the last blood sample is taken.
- Any subject who is not prepared to eat standard meals in the clinic or is a vegetarian.
- Participated in a clinical trial for a new drug within 30 days or 5 half-lives or twice the duration of that drugs effect before the dosing day for this study.
- Exposure to 4 new drugs in clinical trials within the last 12 months before dosing in this study.
- Use of any medications (prescribed or non-prescribed including vitamins and herbal supplements) within 7 days before dosing in this study.
- Participation in this study would result in the subject donating more than 500ml in a 56 day period.
- Regular use of tobacco or nicotine-containing products within 6 months of screening.
- Unwillingness to abstain from sexual intercourse with pregnant or lactating women from dosing until 84 days after.
- Unwillingness to use contraception and have female partner use contraception if she could become pregnant for 84 days after dosing.
- Unwillingness to abstain from strenuous physical activity for 48 hours before screening and in the 72 hours before and 48 hours after the treatment period.
- Administration of radiolabelled substances or exposure to significant radiation (eg serial X-rays or CT scans, barium meal etc)within the past 12 months from screening.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT00520663 History of Changes |
| Other Study ID Numbers: | OXS109139 |
| Study First Received: | August 23, 2007 |
| Last Updated: | May 31, 2012 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by GlaxoSmithKline:
|
Distribution, SB-649868, Healthy, Excretion, |
Sleep disturbances Volunteer, Metabolism, Absorption, |
Additional relevant MeSH terms:
|
Sleep Initiation and Maintenance Disorders Sleep Disorders, Intrinsic Dyssomnias |
Sleep Disorders Nervous System Diseases Mental Disorders |
ClinicalTrials.gov processed this record on May 21, 2013